Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2.taNK - ImmunityBio

Next Previous
Drug Profile

HER2.taNK - ImmunityBio

Alternative Names: CAR-natural killer cell therapy - ImmunityBio; HER2.tank; HER2taNK; NK-92/5.28.z; taNK cells - NantKwest; Target-activated natural killer cells - ImmunityBio

Latest Information Update: 28 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NantKwest
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Glioblastoma

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in Germany (Intracerebral, Injection)
  • 13 Jan 2022 HER2.taNK is still in phase Ib trials for Glioblastoma (Late-stage disease, Recurrent, Second-line therapy or greater) in Germany (Intracerebral, Injection) (ImmunityBio pipeline, January 2022)
  • 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top